Carmichael Hill & Associates’s Gilead Sciences GILD Stock Holding History

Carmichael Hill & Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$420	Hold	5	–	–	﹤0.01%	754
2024 Q2	$344	Hold	5	–	–	﹤0.01%	754
2024 Q1	$367	Hold	5	–	–	﹤0.01%	746
2023 Q4	$406	Hold	5	–	–	﹤0.01%	766
2023 Q3	$375	Hold	5	–	–	﹤0.01%	765
2023 Q2	$386	Sell	5 -63	-93%	-$5.03K	﹤0.01%	762
2023 Q1	$5.64K	Buy	68 +63	+1,260%	+$5.22K	﹤0.01%	627
2022 Q4	$429	Hold	5	–	–	﹤0.01%	752
2022 Q3	$0	Hold	5	–	–	﹤0.01%	835
2022 Q2	$0	Hold	5	–	–	﹤0.01%	834
2022 Q1	$0	Hold	5	–	–	﹤0.01%	812
2021 Q4	$0	Hold	5	–	–	﹤0.01%	816
2021 Q3	$0	Buy	+5	New	+$351	﹤0.01%	804
2020 Q4	–	Sell	-125	Closed	-$7.54K	–	745
2020 Q3	$8K	Sell	125 -40	-24%	-$2.77K	0.01%	545
2020 Q2	$13K	Buy	165 +50	+43%	+$3.83K	0.01%	466
2020 Q1	$9K	Sell	115 -148	-56%	-$10.2K	0.01%	472
2019 Q4	$17K	Buy	+263	New	+$17.1K	0.01%	415

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Carmichael Hill & Associates's GILD Position: Q3 2024 in Review

Carmichael Hill & Associates held its Gilead Sciences (GILD) position steady in Q3 2024 at 5 shares worth $420. The position accounts for ﹤0.01% of the portfolio, ranked #754.

Carmichael Hill & Associates first reported a position in GILD in Q4 2019 and has held it in 17 quarters since. The position peaked at $17K in Q4 2019. 1,718 funds tracked by Wall St. Rank hold GILD as of Q3 2024.

Carmichael Hill & Associates held 5 shares of Gilead Sciences worth $420 as of Q3 2024.
Carmichael Hill & Associates left its Gilead Sciences share count unchanged in Q3 2024.
Gilead Sciences made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #754 holding.
Carmichael Hill & Associates first reported a position in Gilead Sciences in Q4 2019 and has held it in 17 quarters since.
Carmichael Hill & Associates's Gilead Sciences position peaked at $17K in Q4 2019.
1,718 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.